Friedman M J, Stolk J M, Harris P Q, Cooper T B
Biol Psychiatry. 1984 Apr;19(4):557-70.
Three studies were done to determine whether serum dopamine-beta-hydroxylase (DBH) activity is affected by the symptoms of depression or anxiety. In the population-screening study, serum DBH activity was measured in a heterogeneous sample of 548 medical, surgical, and psychiatric outpatients. No association was found between serum DBH activity and scores on either the Zung Self-rating Depression Scale or the Taylor Manifest Anxiety Scale. In the longitudinal depression study, enzyme activity was measured in 14 patients with major depressive illness treated with imipramine. Serum DBH activity remained unchanged throughout treatment whether or not the patient recovered from the depressive illness. Furthermore, there was no association between enzyme activity and steady state antidepressant plasma levels. In the longitudinal anxiety study, evaluation of 45 anxious outpatients in a placebo-controlled double-blind evaluation of two benzodiazepines (diazepam and alprazolam) indicated that serum DBH activity failed to reflect either state changes in anxiety or pharmacological variables. These results are reviewed with respect to current knowledge regarding neuronal release and extraneuronal disposal of circulating DBH.
开展了三项研究以确定血清多巴胺-β-羟化酶（DBH）活性是否受抑郁或焦虑症状影响。在人群筛查研究中，对548名内科、外科和精神科门诊患者的异质样本测量了血清DBH活性。未发现血清DBH活性与zung自评抑郁量表或泰勒显性焦虑量表得分之间存在关联。在纵向抑郁研究中，对14名接受丙咪嗪治疗的重度抑郁病患者测量了酶活性。无论患者是否从抑郁病中康复，整个治疗过程中血清DBH活性均保持不变。此外，酶活性与稳态抗抑郁药血浆水平之间无关联。在纵向焦虑研究中，对45名焦虑门诊患者进行了两种苯二氮䓬类药物（地西泮和阿普唑仑）的安慰剂对照双盲评估，结果表明血清DBH活性未能反映焦虑状态变化或药理学变量。结合目前关于循环DBH的神经元释放和神经元外处置的知识对这些结果进行了综述。
